A low-dose psilocybin capsule, designed to be taken at home

UFC Hall of Famer Michael Bisping Backs Xycota Biosciences’ Low-Dose Psilocybin Research on PTSD and Concussion

Former UFC Middleweight Champion to join Xycota Chief Scientific Officer Marvin S. Hausman, M.D., for an upcoming podcast examining repeated head impact, PTSD, and sub-perceptual psilocybin research targeting brain-repair pathways.

• Public Science Dialogue: UFC Hall of Famer Michael Bisping and Xycota Co-Founder and CSO Marvin S. Hausman, M.D., plan to record a public podcast on concussion, mild traumatic brain injury (mTBI), and mild PTSD.
• Sub-Perceptual Psilocybin Thesis: Xycota is investigating whether low-dose psilocybin can engage the brain’s BDNF/TrkB neuroplasticity pathway at home without hallucinogenic effects.
• Preclinical and Corporate Status: All Xycota candidates remain preclinical and unapproved; BioAdaptives, Inc.’s (OTCID: BDPT) agreement to acquire Xycota remains subject to closing conditions.

LAS VEGAS, Nev. and SHERIDAN, Wyo., November 12, 2026. UFC Hall of Famer, former middleweight champion, and broadcaster Michael Bisping is lending his support to spotlight the preclinical psilocybin neuroscience program at Xycota Biosciences, LLC, which BioAdaptives, Inc. (OTCID: BDPT) has signed a definitive agreement to acquire. Bisping, a paid brand ambassador for BioAdaptives’ MyndSystem™ supplements, plans to join Xycota Co-Founder and Chief Scientific Officer Marvin S. Hausman, M.D., for an unscripted podcast covering repeated head impact in combat sports, PTSD in veterans and first responders, and what published psilocybin research does and does not show. Recording and release details will be announced once finalized.

Xycota’s lead candidate, XYCO-02, is an investigational low-dose oral psilocybin capsule designed for potential at-home use at a sub-perceptual dose intended to produce no noticeable psychedelic effects, with the clinical dose still to be determined. Its first planned clinical target is mild PTSD, alongside early-stage preclinical research in mild traumatic brain injury (mTBI), including concussion. Safety, efficacy, and suitability for at-home use must be established through clinical trials and regulatory review.

Testing brain repair without the six-hour clinic trip

Supervised psychedelic therapy sessions typically require six to eight hours in a clinic, excluding many working families, caregivers, and active-duty personnel. Xycota is testing whether structural repair signaling through the BDNF/TrkB pathway (which supports synaptic connections between nerve cells and is often reduced in PTSD and TBI) can be engaged without a psychedelic experience.

In a 2026 Neuropsychopharmacology study (Ascone et al.) co-authored by Dr. Hausman, repeated low-dose oral psilocybin rescued object-recognition memory in a Fragile X rat model. That benefit persisted in rats when hallucination-linked serotonin receptors were blocked, and vanished when TrkB was blocked. The study was conducted exclusively in rats, did not evaluate PTSD, concussion, or mTBI, and has not been tested in people. Details on the preclinical data and open clinical questions are available at https://xycota.com/science.

About the Companies

Xycota Biosciences, LLC (https://xycota.com), led by Co-Founders Brad Listermann (CEO) and Marvin S. Hausman, M.D. (CSO), is a preclinical neuroscience company developing XYCO-02 for mild PTSD and XYCO-01, an exosome-formulated psilocin candidate for frontotemporal dementia (FDA Orphan Drug Designation request filed, not granted), with early preclinical research in mTBI. BioAdaptives, Inc. (OTCID: BDPT) markets human and animal dietary supplements and signed a definitive agreement on October 29, 2026 to acquire Xycota. The transaction has not closed and remains subject to closing conditions detailed in the Form 8-K filed November 4, 2026 (SEC EDGAR Form 8-K).

Disclosures and Regulatory Information

Michael Bisping is a paid brand ambassador for BioAdaptives’ MyndSystem™ dietary supplements under an agreement announced August 31, 2026. He is not receiving any cash, securities, or additional compensation for this announcement or the planned podcast. MyndSystem™ supplements are unrelated to Xycota’s pharmaceutical programs, have not been evaluated by the FDA, are not intended to diagnose, treat, cure, or prevent any disease, and have not been studied for PTSD or concussion. XYCO-01 and XYCO-02 are preclinical, investigational candidates involving Schedule I controlled substances; neither has been tested in a company-sponsored human trial or approved by the FDA, Health Canada, or any regulator, and no safety or efficacy claims are made. No study is recruiting, and nothing herein is medical advice.

Forward-Looking Statements

This release contains forward-looking statements regarding a planned podcast, preclinical research, potential clinical trials, and the pending Xycota acquisition. Actual results may differ materially. The podcast may not occur as anticipated; acquisition closing and milestone funding depend on unsatisfied conditions; preferred stock and convertible note conversions will dilute BioAdaptives stockholders; regulatory and ethics approvals may be delayed or denied; and animal findings may not translate to humans, PTSD, or mTBI. Review BioAdaptives’ November 4, 2026 Form 8-K and other SEC filings. Statements speak only as of today without update obligation except as required by law. Not an offer to sell or solicitation to buy securities.

Contacts: BioAdaptives, Inc.: Drew@BioAdaptives.com | (702) 659-8829 | X: @BioAdaptivesInc · Xycota Biosciences: Brad Listermann | brad@xycota.com

Xycota Biosciences Launches Free, 100% Private PTSD Community & Resource Hub for Veterans, Active-Duty Service Members, First Responders, and Families

Guided by 37-year combat veteran Lt. Col. Elton Johnson Jr., U.S. Army (Ret.), and physician-scientist Marvin S. Hausman, M.D., every tool on the hub requires zero login, stays off the record, and can be used right from a phone.

SHERIDAN, Wyo., November 11, 2026. Today Xycota Biosciences honors the men and women who stepped forward to serve. Honoring veterans also means confronting the battles too many carry home in silence.

PTSD is not a character flaw or a sign of weakness. Chronic trauma leaves a measurable physical imprint on the brain and nervous system. Yet published epidemiological data shows how heavy and unspoken this reality remains:

• High Lifetime Prevalence: Nearly 29% of Iraq and Afghanistan veterans and 21% of Persian Gulf War veterans experience PTSD at some point in their lives.
• Disconnected from Care: An average of 17.7 veterans die by suicide every day, and 62% were not connected to VA healthcare in the year prior.
• Treatment Gap: Only 27% of veterans who screen positive for a mental health condition currently receive treatment.
• Barriers and Stigma: Nearly half of untreated veterans (47.1%) face barriers to care, with stigma (28.8%) standing out as a primary reason they stay quiet alongside fear of career impact, security clearance issues, or administrative red tape.

Too many veterans say nothing because they do not want to be judged, misunderstood at home, or caught in paperwork traps.

A Free, 100% Private Resource Suite at xycota.com/ptsd

At Xycota Biosciences, we built a free, 100% private PTSD Community & Resource Hub for veterans, active-duty service members, first responders, and their families at https://xycota.com/ptsd.

Guided by 37-year combat veteran Lt. Col. Elton Johnson Jr., U.S. Army (Ret.), and physician-scientist Dr. Marvin S. Hausman, M.D., every tool on the hub requires zero login, stays off the record, and can be used right from your phone:

• Guided Breathing & Grounding Resets: Interactive pacers for the 60-second Stanford physiological sigh, Spec-Ops 4-4-4-4 box breathing, and a 5-4-3-2-1 sensory reset to calm panic and hypervigilance in real time.
• Shareable Family Talking-Point Cards: One-tap copy-and-text cards (“Relational Field Guides”) that help veterans explain crowded-room fatigue, adrenaline spikes, 2:00 AM wake-ups, and discreet public exit signals to a spouse or loved ones without having to find the words in the moment.
• Confidential Support Matcher: Zero-red-tape filtering for vetted organizations (including Vet Centers, The Headstrong Project, Cohen Veterans Network, and Home Base) whose records stay separate from standard VA hospital systems and chain of command.
• Private On-Device Readiness Log & Science Navigator: Track sleep, calm, and focus locally in your browser (never uploaded to any server), plus plain-language answers on the biology of trauma and brain recovery.

Try the tools for free today or send the hub to a veteran you care about: https://xycota.com/ptsd.

Disclosures and Regulatory Information

The Xycota PTSD Community & Resource Hub is an educational and peer-support resource only and does not provide medical advice, diagnosis, or treatment. If you or someone you know is in crisis, call or text 988 (Veterans Crisis Line: dial 988 then press 1, or text 838255). All Xycota Biosciences pharmaceutical programs (XYCO-02 and XYCO-01) are preclinical and investigational and have not been approved by the FDA, Health Canada, or any regulatory authority. BioAdaptives, Inc. (OTCID: BDPT) has signed a definitive agreement to acquire Xycota Biosciences, LLC, reported on SEC Form 8-K filed November 4, 2026; the transaction has not closed and remains subject to closing conditions.

BioAdaptives to Acquire Xycota Biosciences to Pursue the Potential of At-Home Psilocybin Treatment

Xycota’s lead program aims to deliver clinical benefit from low-dose psilocybin without hallucinogenic effects, with mild PTSD as its initial target.

LAS VEGAS, NV AND SHERIDAN, WY / ACCESS Newswire / November 5, 2026 / BioAdaptives, Inc. (OTCID: BDPT) has signed a definitive agreement to acquire Xycota Biosciences, LLC, a preclinical biotechnology company pursuing an ambitious goal: an oral psilocybin treatment that patients could take at home without hallucinogenic effects. The agreement, dated October 29, 2026, would bring Xycota’s CNS drug-development programs into BioAdaptives. The transaction has not closed and remains subject to closing conditions.

An opportunity to change how treatment reaches patients

Xycota’s thesis reaches beyond the molecule to how treatment could fit into everyday life. If a low-dose oral medicine can deliver meaningful benefit without requiring prolonged supervised psychedelic sessions, it could reduce the time and logistical burden on patients and create a more scalable treatment model. For BioAdaptives stockholders, the proposed acquisition offers participation in developing that possibility, beginning with mild post-traumatic stress disorder (PTSD). Safety, efficacy and suitability for at-home use would need to be established through clinical development and regulatory review.

The scientific starting point is a 2026 study published in Neuropsychopharmacology and co-authored by Xycota Chief Scientific Officer Marvin S. Hausman, M.D. Repeated low-dose psilocybin improved recognition memory in a rat model of Fragile X syndrome, with findings supporting a role for BDNF/TrkB signaling, a pathway involved in neuroplasticity. For Xycota, that finding provides a rationale to investigate whether low-dose treatment can produce clinical benefit without hallucinogenic effects. The study did not evaluate PTSD or human subjects; translating the animal findings into an effective medicine remains the central development challenge.

The lead candidate, XYCO-02, is low-dose oral psilocybin intended to be sub-perceptual, with the clinical dose still to be determined. Xycota’s pipeline also includes XYCO-01, an exosome-formulated psilocin candidate for frontotemporal dementia, and early preclinical research in traumatic brain injury and cognitive aging. An FDA Orphan Drug Designation request for XYCO-01 is on file and has not been granted.

Transaction Structure and Governance

At closing, Xycota would become a wholly owned subsidiary of BioAdaptives and continue under its existing executive and scientific leadership, including Co-Founders Brad Listermann, Chief Executive Officer, and Dr. Hausman. The acquisition consideration is payable to the Xycota members who are parties to the agreement, rather than to Xycota itself. No cash purchase price is payable.

BioAdaptives is obligated to issue Economic Preferred stock within 20 business days after closing, representing 40% of its total voting power and economic ownership immediately after issuance, as specified in the agreement. Separate Voting Preferred stock carrying 51% of total voting power is initially issuable to BioAdaptives CEO James E. Keener and transfers to the Xycota members upon specified regulatory or clinical milestones, a nutraceutical spin-off, or another transfer event defined in the agreement. These voting rights are distinct from economic ownership. If closing has not occurred by June 30, 2027, the agreement terminates automatically.

The agreement provides for separate Xycota bank accounts under its management’s signatory control and contractual restrictions on using Xycota intellectual property or dedicated cash for BioAdaptives’ legacy nutraceutical obligations or parent overhead. BioAdaptives’ existing nutraceutical operations would continue separately. A possible spin-off is subject to the agreement; the Xycota founders and their affiliates would receive no interest in that spin-off entity.

No funding has been received under the agreement, and none is payable before closing. After closing, the investors have agreed to provide $150,000 in four tranches, subject to spending certification. Additional investment rights of up to $800,000 over 36 months comprise a $400,000 milestone-triggered call, subject to a Control Event and Rule 144 issuer conditions, and a separate $400,000 optional investment. The agreement also provides for up to $160,000 for reporting and spin-off costs, with conditions applying to spin-off funding. These amounts are not unrestricted cash available at closing.

Funding is through 12-month convertible notes carrying a 10% original issue discount and a 10% one-time interest charge. The agreement includes founder lockups and restrictions on resales by specified holders. These restrictions do not eliminate dilution: issuance and conversion of preferred stock and convertible notes will dilute existing stockholders. The Form 8-K and its agreement exhibit describe the financing conditions, transfer restrictions and other terms.

About the Companies and Forward-Looking Statements

BioAdaptives, Inc. (OTCID: BDPT) is a nutraceutical supplier. Xycota Biosciences, LLC is a preclinical CNS company led by Brad Listermann and Marvin S. Hausman, M.D. Lead Scientist Viviana Trezza, Ph.D., is Associate Professor at Roma Tre University. Psilocybin and psilocin are Schedule I controlled substances in the United States. No Xycota product has been tested in a company-sponsored human study or approved by any regulator.

This release contains forward-looking statements about closing, financing, control changes, a possible spin-off and Xycota’s programs. Actual results may differ materially. Closing and funding depend on conditions that may not be satisfied. Issuance and conversion of preferred stock and notes will dilute stockholders. Xycota’s candidates are preclinical, involve controlled substances and require regulatory and ethics approvals that may be delayed or denied. Animal findings may not translate to humans. A Control Event or spin-off may never occur. The stock is thinly traded and may be volatile. Readers should review the Form 8-K filed November 4, 2026 and the company’s other SEC filings. Statements speak only as of this date, with no update obligation except as required by law. This release is not an offer to sell securities.

Contacts: BioAdaptives, Inc.: Drew@BioAdaptives.com | (702) 659-8829 | X: @BioAdaptivesInc · Xycota Biosciences: Brad Listermann | brad@xycota.com

BioAdaptives, Inc. Files SEC Form 8-K Current Report Disclosing Definitive Agreement to Acquire Xycota Biosciences, LLC

Current Report on Form 8-K (Items 1.01 and 3.02) and Exhibit 10.1 set forth the October 29, 2026 acquisition agreement, governance structure, and milestone-linked note financing terms.

WASHINGTON, D.C. / SEC EDGAR / November 4, 2026. BioAdaptives, Inc. (OTCID: BDPT) filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission reporting that on October 29, 2026, BioAdaptives entered into a definitive agreement to acquire Xycota Biosciences, LLC, a Wyoming preclinical CNS biotechnology company led by Co-Founders Brad Listermann (Chief Executive Officer) and Marvin S. Hausman, M.D. (Chief Scientific Officer).

Key Provisions Disclosed in the Form 8-K

• Wholly Owned Subsidiary & Ring-Fenced Operations: At closing, Xycota would become a wholly owned subsidiary of BioAdaptives operating under its existing management, with dedicated Xycota bank accounts under Xycota management’s signatory control and contractual restrictions barring the use of Xycota IP or dedicated cash for legacy parent obligations.
• Equity & Voting Structure: Within 20 business days after closing, BioAdaptives is obligated to issue Economic Preferred stock representing 40% of total voting power and economic ownership immediately after issuance. Separate Voting Preferred stock carrying 51% of total voting power is initially issuable to BioAdaptives CEO James E. Keener and transfers to the Xycota members upon specified regulatory or clinical milestones, a nutraceutical spin-off, or another defined transfer event.
• Tranched Convertible Note Financing Commitments: No funding is payable before closing. Post-closing commitments include $150,000 across four tranches subject to spending certification, plus additional investment rights of up to $800,000 over 36 months ($400,000 milestone-triggered call subject to a Control Event and Rule 144 conditions, and $400,000 optional investment) and up to $160,000 for reporting and spin-off costs.
• Closing Conditions & Outside Date: The transaction has not closed and remains subject to closing conditions. If closing has not occurred by June 30, 2027, the agreement terminates automatically.

All Xycota Biosciences candidates (XYCO-02 and XYCO-01) are preclinical and investigational and have not been approved by the FDA, Health Canada, or any regulatory authority. Readers should review the complete Form 8-K and Exhibit 10.1 on SEC EDGAR for full terms, risk factors, and dilution disclosures.